Compare · ADVM vs MRNA
ADVM vs MRNA
Side-by-side comparison of Adverum Biotechnologies Inc. (ADVM) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADVM and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $57.40B, about 377.3x ADVM ($152.1M).
- Over the past year, ADVM is up 46.6% and MRNA is up 478.7% - MRNA leads by 432.0 points.
- MRNA has hit the wire 19 times in the past 4 weeks while ADVM has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 7 for ADVM).
- Company
- Adverum Biotechnologies Inc.
- Moderna Inc.
- Price
- $4.37+2.58%
- $143.74-2.01%
- Market cap
- $152.1M
- $57.40B
- 1M return
- +2.10%
- +127.13%
- 1Y return
- +46.64%
- +478.66%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2018
- News (4w)
- 0
- 19
- Recent ratings
- 7
- 25
Adverum Biotechnologies Inc.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest ADVM
- SEC Form 15-12G filed by Adverum Biotechnologies Inc.
- SEC Form EFFECT filed by Adverum Biotechnologies Inc.
- SEC Form EFFECT filed by Adverum Biotechnologies Inc.
- SEC Form EFFECT filed by Adverum Biotechnologies Inc.
- CEO, PRESIDENT AND DIRECTOR Fischer Laurent exercised 150,000 shares at a strike of $4.20 and was granted 500,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- CHIEF OPERATING OFFICER Soparkar Peter was granted 150,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Ozden Rabia Gurses was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)
- CHIEF FINANCIAL OFFICER Rubinstein Linda M was granted 42,000 units of Common Stock - Performance Stock Units and exercised 48,750 shares at a strike of $4.20, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Hong Soo
Latest MRNA
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Mock James M exercised 19,836 shares at a strike of $30.96 and sold $4,685,094 worth of shares (34,836 units at $134.49) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 59,375 units (SEC Form 4)
- Chief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 9% to 74,375 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 8% to 81,340 units (SEC Form 4) (withholding obligation)
- Chief Legal Officer Klinger Shannon Thyme sold $485,766 worth of shares (3,471 units at $139.95) as part of a pre-agreed trading plan, covered exercise/tax liability with 1,048 shares and exercised 5,637 shares at a strike of $19.06, increasing direct ownership by 2% to 75,247 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M covered exercise/tax liability with 1,197 shares and converted options into 2,475 shares, increasing direct ownership by 2% to 68,282 units (SEC Form 4) (for withholding tax)
- President Hoge Stephen converted options into 9,283 shares and covered exercise/tax liability with 4,489 shares, increasing direct ownership by 0.32% to 1,489,699 units (SEC Form 4) (tax liability)
- Moderna downgraded by Rothschild & Co Redburn with a new price target
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Moderna to Present at Upcoming Conferences in September 2026